News | February 07, 2014

Corus CAD Gene Expression Test Correlates With Plaque Burden, Obstructive Coronary Artery Disease

Study results validated by CT angiography

February 7, 2014 — CardioDx Inc. is a molecular diagnostics company specializing in cardiovascular genomics. It published an analysis demonstrating that the Corus CAD gene expression score is significantly associated with plaque burden and luminal stenosis. The holds true in symptomatic patients being evaluated for obstructive coronary artery disease (CAD), as measured by CT-angiography. The study, "A Peripheral Blood Gene Expression Score is Associated with Atherosclerotic Plaque Burden and Stenosis by Cardiovascular CT-Angiography," appears online in the journal Atherosclerosis.
"Our understanding of the relationship between peripheral blood gene expression, as measured by the Corus CAD gene expression score, and plaque composition and stenosis determined by CT-angiography continues to grow," said Steven Rosenberg, Ph.D., senior author and a member of CardioDx's Scientific Advisory Board. "These findings are important as they show that the Corus CAD score, which provides an estimate of a patient's likelihood of obstructive CAD, offers additional information related to disease burden that is useful in the diagnostic evaluation of the patient."
In this subgroup analysis, which included 610 patients from the PREDICT and COMPASS studies, the Corus CAD gene expression score was significantly associated with plaque burden (p < 0.001) and luminal stenosis (p < 0.01) as measured by CT-angiography. Additionally, the Corus CAD gene expression score was a stronger predictor of stenosis, as compared to the Diamond-Forrester clinical classification. Furthermore, an increasingly higher Corus CAD gene expression score was associated with increasing maximal stenosis, as determined by CT-angiography (p < 0.001).
Corus CAD is a blood test that can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms are due to obstructive CAD. 
For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init